nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Erythropenia—Riluzole—amyotrophic lateral sclerosis	0.0564	0.0916	CcSEcCtD
Everolimus—MTOR—forelimb—amyotrophic lateral sclerosis	0.043	0.203	CbGeAlD
Everolimus—MTOR—hindlimb—amyotrophic lateral sclerosis	0.0387	0.183	CbGeAlD
Everolimus—MTOR—appendage—amyotrophic lateral sclerosis	0.0332	0.157	CbGeAlD
Everolimus—Peritonitis—Riluzole—amyotrophic lateral sclerosis	0.0186	0.0302	CcSEcCtD
Everolimus—MTOR—hindbrain—amyotrophic lateral sclerosis	0.0176	0.0832	CbGeAlD
Everolimus—Osteonecrosis—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0205	CcSEcCtD
Everolimus—Pyelonephritis—Riluzole—amyotrophic lateral sclerosis	0.0124	0.0201	CcSEcCtD
Everolimus—Cheilitis—Riluzole—amyotrophic lateral sclerosis	0.0111	0.018	CcSEcCtD
Everolimus—MTOR—embryo—amyotrophic lateral sclerosis	0.011	0.052	CbGeAlD
Everolimus—MTOR—brainstem—amyotrophic lateral sclerosis	0.0101	0.0477	CbGeAlD
Everolimus—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.00944	0.0153	CcSEcCtD
Everolimus—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.00944	0.0153	CcSEcCtD
Everolimus—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00918	0.0149	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—PTPRZ1—amyotrophic lateral sclerosis	0.00906	0.0525	CbGpPWpGaD
Everolimus—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00838	0.0136	CcSEcCtD
Everolimus—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00828	0.0135	CcSEcCtD
Everolimus—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00818	0.0133	CcSEcCtD
Everolimus—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.0079	0.0128	CcSEcCtD
Everolimus—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.0079	0.0128	CcSEcCtD
Everolimus—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.0074	0.012	CcSEcCtD
Everolimus—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.0074	0.012	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—GABARAPL2—amyotrophic lateral sclerosis	0.00738	0.0428	CbGpPWpGaD
Everolimus—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00732	0.0119	CcSEcCtD
Everolimus—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00683	0.0111	CcSEcCtD
Everolimus—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00676	0.011	CcSEcCtD
Everolimus—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00676	0.011	CcSEcCtD
Everolimus—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00664	0.0108	CcSEcCtD
Everolimus—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00664	0.0108	CcSEcCtD
Everolimus—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00664	0.0108	CcSEcCtD
Everolimus—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00658	0.0107	CcSEcCtD
Everolimus—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00635	0.0103	CcSEcCtD
Everolimus—FKBP1A—medulla oblongata—amyotrophic lateral sclerosis	0.00634	0.0299	CbGeAlD
Everolimus—MTOR—spinal cord—amyotrophic lateral sclerosis	0.00629	0.0296	CbGeAlD
Everolimus—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00613	0.00997	CcSEcCtD
Everolimus—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.0058	0.00942	CcSEcCtD
Everolimus—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00567	0.00921	CcSEcCtD
Everolimus—FKBP1A—spinal cord—amyotrophic lateral sclerosis	0.00565	0.0267	CbGeAlD
Everolimus—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00535	0.00869	CcSEcCtD
Everolimus—MTOR—nervous system—amyotrophic lateral sclerosis	0.0053	0.025	CbGeAlD
Everolimus—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00517	0.00839	CcSEcCtD
Everolimus—MTOR—central nervous system—amyotrophic lateral sclerosis	0.0051	0.0241	CbGeAlD
Everolimus—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.0051	0.00828	CcSEcCtD
Everolimus—Gout—Riluzole—amyotrophic lateral sclerosis	0.00503	0.00818	CcSEcCtD
Everolimus—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.005	0.00812	CcSEcCtD
Everolimus—MTOR—cerebellum—amyotrophic lateral sclerosis	0.00498	0.0235	CbGeAlD
Everolimus—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00497	0.00807	CcSEcCtD
Everolimus—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00497	0.00807	CcSEcCtD
Everolimus—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00494	0.00802	CcSEcCtD
Everolimus—FKBP1A—nervous system—amyotrophic lateral sclerosis	0.00476	0.0225	CbGeAlD
Everolimus—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.0047	0.00763	CcSEcCtD
Everolimus—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.0047	0.00763	CcSEcCtD
Everolimus—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.0047	0.00763	CcSEcCtD
Everolimus—MTOR—Cellular response to heat stress—VCP—amyotrophic lateral sclerosis	0.00467	0.0271	CbGpPWpGaD
Everolimus—FKBP1A—central nervous system—amyotrophic lateral sclerosis	0.00459	0.0216	CbGeAlD
Everolimus—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00449	0.00729	CcSEcCtD
Everolimus—FKBP1A—cerebellum—amyotrophic lateral sclerosis	0.00448	0.0211	CbGeAlD
Everolimus—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00446	0.00725	CcSEcCtD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—amyotrophic lateral sclerosis	0.00433	0.0251	CbGpPWpGaD
Everolimus—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00425	0.0069	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—GRN—amyotrophic lateral sclerosis	0.00418	0.0242	CbGpPWpGaD
Everolimus—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00418	0.00679	CcSEcCtD
Everolimus—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00408	0.00662	CcSEcCtD
Everolimus—MTOR—brain—amyotrophic lateral sclerosis	0.00405	0.0191	CbGeAlD
Everolimus—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.004	0.00649	CcSEcCtD
Everolimus—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00392	0.00637	CcSEcCtD
Everolimus—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00392	0.00637	CcSEcCtD
Everolimus—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00611	CcSEcCtD
Everolimus—FKBP1A—brain—amyotrophic lateral sclerosis	0.00364	0.0172	CbGeAlD
Everolimus—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00361	0.00587	CcSEcCtD
Everolimus—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.0036	0.00585	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	0.00354	0.0205	CbGpPWpGaD
Everolimus—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00349	0.00568	CcSEcCtD
Everolimus—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00342	0.00556	CcSEcCtD
Everolimus—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00336	0.00545	CcSEcCtD
Everolimus—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00324	0.00527	CcSEcCtD
Everolimus—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00324	0.00527	CcSEcCtD
Everolimus—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00317	0.00515	CcSEcCtD
Everolimus—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00315	0.00512	CcSEcCtD
Everolimus—MTOR—LKB1 signaling events—MAPT—amyotrophic lateral sclerosis	0.00313	0.0181	CbGpPWpGaD
Everolimus—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00504	CcSEcCtD
Everolimus—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00308	0.00501	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00499	CcSEcCtD
Everolimus—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00302	0.0049	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.00301	0.0174	CbGpPWpGaD
Everolimus—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00489	CcSEcCtD
Everolimus—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00489	CcSEcCtD
Everolimus—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00297	0.00482	CcSEcCtD
Everolimus—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00479	CcSEcCtD
Everolimus—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00479	CcSEcCtD
Everolimus—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00289	0.0047	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	0.00288	0.0167	CbGpPWpGaD
Everolimus—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00287	0.00467	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	0.00285	0.0165	CbGpPWpGaD
Everolimus—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00461	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—PTPRF—amyotrophic lateral sclerosis	0.0028	0.0162	CbGpPWpGaD
Everolimus—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00455	CcSEcCtD
Everolimus—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00276	0.00448	CcSEcCtD
Everolimus—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00276	0.00448	CcSEcCtD
Everolimus—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00272	0.00442	CcSEcCtD
Everolimus—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00271	0.00441	CcSEcCtD
Everolimus—MTOR—FSH signaling pathway—BDNF—amyotrophic lateral sclerosis	0.0027	0.0156	CbGpPWpGaD
Everolimus—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00433	CcSEcCtD
Everolimus—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00264	0.0043	CcSEcCtD
Everolimus—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00427	CcSEcCtD
Everolimus—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00427	CcSEcCtD
Everolimus—MTOR—Class I PI3K signaling events mediated by Akt—CASP9—amyotrophic lateral sclerosis	0.0026	0.0151	CbGpPWpGaD
Everolimus—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00259	0.00421	CcSEcCtD
Everolimus—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00419	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—PTPRF—amyotrophic lateral sclerosis	0.00257	0.0149	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAB5A—amyotrophic lateral sclerosis	0.00257	0.0149	CbGpPWpGaD
Everolimus—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00416	CcSEcCtD
Everolimus—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00416	CcSEcCtD
Everolimus—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00415	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—ATXN2—amyotrophic lateral sclerosis	0.00255	0.0148	CbGpPWpGaD
Everolimus—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00407	CcSEcCtD
Everolimus—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00249	0.00404	CcSEcCtD
Everolimus—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00248	0.00403	CcSEcCtD
Everolimus—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00401	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.00245	0.0142	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—PTGS2—amyotrophic lateral sclerosis	0.00244	0.0141	CbGpPWpGaD
Everolimus—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00385	CcSEcCtD
Everolimus—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00384	CcSEcCtD
Everolimus—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00383	CcSEcCtD
Everolimus—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00383	CcSEcCtD
Everolimus—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00381	CcSEcCtD
Everolimus—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00381	CcSEcCtD
Everolimus—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00234	0.0038	CcSEcCtD
Everolimus—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00233	0.00379	CcSEcCtD
Everolimus—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00378	CcSEcCtD
Everolimus—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00232	0.00377	CcSEcCtD
Everolimus—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00376	CcSEcCtD
Everolimus—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00358	CcSEcCtD
Everolimus—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00219	0.00356	CcSEcCtD
Everolimus—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00348	CcSEcCtD
Everolimus—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00346	CcSEcCtD
Everolimus—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00345	CcSEcCtD
Everolimus—Chills—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00344	CcSEcCtD
Everolimus—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00339	CcSEcCtD
Everolimus—MTOR—ErbB1 downstream signaling—RAB5A—amyotrophic lateral sclerosis	0.00207	0.012	CbGpPWpGaD
Everolimus—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00207	0.00336	CcSEcCtD
Everolimus—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00334	CcSEcCtD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—SQSTM1—amyotrophic lateral sclerosis	0.00203	0.0118	CbGpPWpGaD
Everolimus—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00329	CcSEcCtD
Everolimus—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00327	CcSEcCtD
Everolimus—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00323	CcSEcCtD
Everolimus—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00321	CcSEcCtD
Everolimus—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00313	CcSEcCtD
Everolimus—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00191	0.0031	CcSEcCtD
Everolimus—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00308	CcSEcCtD
Everolimus—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00307	CcSEcCtD
Everolimus—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00305	CcSEcCtD
Everolimus—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00301	CcSEcCtD
Everolimus—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00299	CcSEcCtD
Everolimus—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00299	CcSEcCtD
Everolimus—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00295	CcSEcCtD
Everolimus—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00293	CcSEcCtD
Everolimus—Cough—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00291	CcSEcCtD
Everolimus—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00289	CcSEcCtD
Everolimus—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00288	CcSEcCtD
Everolimus—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00284	CcSEcCtD
Everolimus—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00284	CcSEcCtD
Everolimus—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00284	CcSEcCtD
Everolimus—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00283	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00282	CcSEcCtD
Everolimus—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00281	CcSEcCtD
Everolimus—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00278	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.00169	0.00978	CbGpPWpGaD
Everolimus—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00272	CcSEcCtD
Everolimus—Infection—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00271	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—GRIA2—amyotrophic lateral sclerosis	0.00167	0.00965	CbGpPWpGaD
Everolimus—Shock—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00268	CcSEcCtD
Everolimus—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00267	CcSEcCtD
Everolimus—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00267	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.00164	0.00949	CbGpPWpGaD
Everolimus—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00266	CcSEcCtD
Everolimus—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00265	CcSEcCtD
Everolimus—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00263	CcSEcCtD
Everolimus—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.0016	0.0026	CcSEcCtD
Everolimus—MTOR—ErbB Signaling Pathway—ERBB4—amyotrophic lateral sclerosis	0.00157	0.00912	CbGpPWpGaD
Everolimus—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00254	CcSEcCtD
Everolimus—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.00156	0.00734	CbGeAlD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.00154	0.00893	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00248	CcSEcCtD
Everolimus—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00246	CcSEcCtD
Everolimus—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00245	CcSEcCtD
Everolimus—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.0015	0.00707	CbGeAlD
Everolimus—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00243	CcSEcCtD
Everolimus—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00242	CcSEcCtD
Everolimus—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00148	0.0024	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.00147	0.00855	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—RAB5A—amyotrophic lateral sclerosis	0.00146	0.00848	CbGpPWpGaD
Everolimus—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00237	CcSEcCtD
Everolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00146	0.00844	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00235	CcSEcCtD
Everolimus—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00235	CcSEcCtD
Everolimus—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00233	CcSEcCtD
Everolimus—Pain—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00233	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IGFBP3—amyotrophic lateral sclerosis	0.0014	0.0081	CbGpPWpGaD
Everolimus—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00224	CcSEcCtD
Everolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.00138	0.00798	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00223	CcSEcCtD
Everolimus—MTOR—IL4-mediated signaling events—CD40LG—amyotrophic lateral sclerosis	0.00133	0.00768	CbGpPWpGaD
Everolimus—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00215	CcSEcCtD
Everolimus—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00215	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—GFAP—amyotrophic lateral sclerosis	0.00132	0.00767	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—CASP9—amyotrophic lateral sclerosis	0.00127	0.00735	CbGpPWpGaD
Everolimus—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00201	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—SQSTM1—amyotrophic lateral sclerosis	0.00121	0.00701	CbGpPWpGaD
Everolimus—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00195	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.00119	0.0069	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—MAPT—amyotrophic lateral sclerosis	0.00119	0.00689	CbGpPWpGaD
Everolimus—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00193	CcSEcCtD
Everolimus—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00186	CcSEcCtD
Everolimus—MTOR—PI-3K cascade—CASP9—amyotrophic lateral sclerosis	0.00114	0.00662	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—ATF1—amyotrophic lateral sclerosis	0.00113	0.00657	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—CASP9—amyotrophic lateral sclerosis	0.00111	0.00646	CbGpPWpGaD
Everolimus—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00111	0.0018	CcSEcCtD
Everolimus—MTOR—GAB1 signalosome—CASP9—amyotrophic lateral sclerosis	0.00111	0.00641	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—ERBB4—amyotrophic lateral sclerosis	0.00108	0.00629	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—CASP9—amyotrophic lateral sclerosis	0.00108	0.00626	CbGpPWpGaD
Everolimus—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00173	CcSEcCtD
Everolimus—Rash—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00172	CcSEcCtD
Everolimus—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00172	CcSEcCtD
Everolimus—Headache—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00171	CcSEcCtD
Everolimus—FKBP1A—Disease—TPK1—amyotrophic lateral sclerosis	0.00104	0.00601	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—GSR—amyotrophic lateral sclerosis	0.00103	0.00594	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.001	0.00581	CbGpPWpGaD
Everolimus—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000996	0.00162	CcSEcCtD
Everolimus—MTOR—Cardiac Hypertrophic Response—IGF1—amyotrophic lateral sclerosis	0.000992	0.00575	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VCP—amyotrophic lateral sclerosis	0.00099	0.00574	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—RTN4—amyotrophic lateral sclerosis	0.00098	0.00568	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—ERBB4—amyotrophic lateral sclerosis	0.000977	0.00566	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000958	0.00555	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—ERBB4—amyotrophic lateral sclerosis	0.000954	0.00553	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—ERBB4—amyotrophic lateral sclerosis	0.000946	0.00548	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—SQSTM1—amyotrophic lateral sclerosis	0.000939	0.00544	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—ERBB4—amyotrophic lateral sclerosis	0.000925	0.00536	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—CASP9—amyotrophic lateral sclerosis	0.000853	0.00495	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	0.000848	0.00492	CbGpPWpGaD
Everolimus—FKBP1A—Disease—VTA1—amyotrophic lateral sclerosis	0.000829	0.00481	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—CASP9—amyotrophic lateral sclerosis	0.000817	0.00473	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000808	0.00468	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—CASP9—amyotrophic lateral sclerosis	0.000804	0.00466	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—ATF1—amyotrophic lateral sclerosis	0.000802	0.00465	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—PTGS2—amyotrophic lateral sclerosis	0.000794	0.0046	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000789	0.00457	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—CASP9—amyotrophic lateral sclerosis	0.000768	0.00445	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—CASP9—amyotrophic lateral sclerosis	0.000764	0.00443	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—CASP9—amyotrophic lateral sclerosis	0.00076	0.0044	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—CASP9—amyotrophic lateral sclerosis	0.000756	0.00438	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—CASP9—amyotrophic lateral sclerosis	0.000745	0.00432	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	0.000737	0.00427	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—ERBB4—amyotrophic lateral sclerosis	0.00073	0.00423	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—CASP9—amyotrophic lateral sclerosis	0.000711	0.00412	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—CASP9—amyotrophic lateral sclerosis	0.000711	0.00412	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—CASP9—amyotrophic lateral sclerosis	0.000711	0.00412	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—BDNF—amyotrophic lateral sclerosis	0.000707	0.0041	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—IGF1—amyotrophic lateral sclerosis	0.000707	0.0041	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—CASP9—amyotrophic lateral sclerosis	0.000705	0.00409	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—ERBB4—amyotrophic lateral sclerosis	0.000699	0.00405	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—CASP9—amyotrophic lateral sclerosis	0.000699	0.00405	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	0.000696	0.00404	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—CASP9—amyotrophic lateral sclerosis	0.000696	0.00403	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—ERBB4—amyotrophic lateral sclerosis	0.000688	0.00399	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IGF1—amyotrophic lateral sclerosis	0.000675	0.00391	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000668	0.00387	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ATF1—amyotrophic lateral sclerosis	0.000662	0.00383	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CASP9—amyotrophic lateral sclerosis	0.000658	0.00382	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IGF1—amyotrophic lateral sclerosis	0.000657	0.00381	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—ERBB4—amyotrophic lateral sclerosis	0.000657	0.00381	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—ERBB4—amyotrophic lateral sclerosis	0.000654	0.00379	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000651	0.00377	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—ERBB4—amyotrophic lateral sclerosis	0.00065	0.00377	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—ERBB4—amyotrophic lateral sclerosis	0.000647	0.00375	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB4—amyotrophic lateral sclerosis	0.000638	0.0037	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CASP9—amyotrophic lateral sclerosis	0.00063	0.00365	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000628	0.00364	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—ERBB4—amyotrophic lateral sclerosis	0.000609	0.00353	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB4—amyotrophic lateral sclerosis	0.000609	0.00353	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—ERBB4—amyotrophic lateral sclerosis	0.000609	0.00353	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—ERBB4—amyotrophic lateral sclerosis	0.000604	0.0035	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—ERBB4—amyotrophic lateral sclerosis	0.000598	0.00347	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—amyotrophic lateral sclerosis	0.000596	0.00345	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—ERBB4—amyotrophic lateral sclerosis	0.000596	0.00345	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IGF1—amyotrophic lateral sclerosis	0.000591	0.00343	CbGpPWpGaD
Everolimus—MTOR—Disease—TPK1—amyotrophic lateral sclerosis	0.000583	0.00338	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PLB1—amyotrophic lateral sclerosis	0.000568	0.00329	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—amyotrophic lateral sclerosis	0.000567	0.00328	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—ERBB4—amyotrophic lateral sclerosis	0.000564	0.00327	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—SQSTM1—amyotrophic lateral sclerosis	0.000543	0.00314	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.00054	0.00313	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB4—amyotrophic lateral sclerosis	0.000539	0.00313	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—MMP9—amyotrophic lateral sclerosis	0.000514	0.00298	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ATF1—amyotrophic lateral sclerosis	0.000509	0.00295	CbGpPWpGaD
Everolimus—FKBP1A—Disease—VCP—amyotrophic lateral sclerosis	0.000507	0.00294	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000501	0.00291	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000497	0.00288	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.000485	0.00281	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000479	0.00277	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	0.000472	0.00274	CbGpPWpGaD
Everolimus—MTOR—Disease—VTA1—amyotrophic lateral sclerosis	0.000466	0.0027	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.000465	0.0027	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—SOD1—amyotrophic lateral sclerosis	0.000464	0.00269	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—GSTP1—amyotrophic lateral sclerosis	0.000453	0.00262	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000428	0.00248	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000425	0.00247	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000415	0.0024	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—amyotrophic lateral sclerosis	0.000408	0.00237	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000398	0.00231	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	0.00038	0.0022	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000378	0.00219	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000374	0.00217	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CST3—amyotrophic lateral sclerosis	0.000364	0.00211	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	0.000359	0.00208	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000355	0.00206	CbGpPWpGaD
Everolimus—MTOR—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000353	0.00205	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000353	0.00205	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000344	0.00199	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.00034	0.00197	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.00034	0.00197	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000321	0.00186	CbGpPWpGaD
Everolimus—MTOR—Disease—PLB1—amyotrophic lateral sclerosis	0.00032	0.00185	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000305	0.00177	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000302	0.00175	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	0.000292	0.00169	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.00029	0.00168	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000289	0.00167	CbGpPWpGaD
Everolimus—MTOR—Disease—VCP—amyotrophic lateral sclerosis	0.000285	0.00165	CbGpPWpGaD
Everolimus—MTOR—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000282	0.00164	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000276	0.0016	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000265	0.00154	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CASP9—amyotrophic lateral sclerosis	0.000264	0.00153	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000237	0.00137	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000227	0.00132	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB4—amyotrophic lateral sclerosis	0.000226	0.00131	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000224	0.0013	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000218	0.00126	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.000214	0.00124	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.00021	0.00122	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000207	0.0012	CbGpPWpGaD
Everolimus—MTOR—Disease—CST3—amyotrophic lateral sclerosis	0.000204	0.00118	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.000204	0.00118	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000199	0.00116	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000197	0.00114	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000194	0.00113	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000193	0.00112	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—C3—amyotrophic lateral sclerosis	0.000189	0.00109	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000185	0.00107	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VEGFA—amyotrophic lateral sclerosis	0.000185	0.00107	CbGpPWpGaD
Everolimus—MTOR—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.00018	0.00104	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APOE—amyotrophic lateral sclerosis	0.000175	0.00101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000172	0.000994	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.00017	0.000983	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000169	0.00098	CbGpPWpGaD
Everolimus—MTOR—Immune System—ATF1—amyotrophic lateral sclerosis	0.000169	0.00098	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000167	0.000966	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP9—amyotrophic lateral sclerosis	0.000161	0.000933	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000158	0.000918	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000149	0.000863	CbGpPWpGaD
Everolimus—MTOR—Disease—CASP9—amyotrophic lateral sclerosis	0.000149	0.000861	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	0.00014	0.000809	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000138	0.000799	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000132	0.000763	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00013	0.000751	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00013	0.000751	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40LG—amyotrophic lateral sclerosis	0.00013	0.000751	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB4—amyotrophic lateral sclerosis	0.000127	0.000737	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000123	0.00071	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—amyotrophic lateral sclerosis	0.00012	0.000695	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000119	0.000687	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000117	0.000675	CbGpPWpGaD
Everolimus—MTOR—Immune System—C3—amyotrophic lateral sclerosis	0.000115	0.000664	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00011	0.000638	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000109	0.000633	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000104	0.000603	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000104	0.0006	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000101	0.000587	CbGpPWpGaD
Everolimus—MTOR—Disease—APOE—amyotrophic lateral sclerosis	9.84e-05	0.00057	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	9.37e-05	0.000543	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.91e-05	0.000516	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.38e-05	0.000485	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.79e-05	0.000452	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.4e-05	0.000429	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.37e-05	0.000427	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	7.1e-05	0.000411	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.89e-05	0.000399	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—amyotrophic lateral sclerosis	6.74e-05	0.000391	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.61e-05	0.000383	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	6.55e-05	0.00038	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.7e-05	0.00033	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	5.38e-05	0.000312	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5e-05	0.00029	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.38e-05	0.000254	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.14e-05	0.00024	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.72e-05	0.000216	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.89e-05	0.000168	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.81e-05	0.000163	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.66e-05	0.000154	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	2.19e-05	0.000127	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.5e-05	8.68e-05	CbGpPWpGaD
